Skip to content
The Microdose (UC Berkeley BCSP)· jane c. hu·· 28 days agoAI score44

ICER to review Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression

Healthcare cost watchdog to scrutinize Compass’s synthetic psilocybin, and Study links enhanced feelings of connection to lighter depression following psilocybin

AI summary

The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depressionDepression that has not improved enough after adequate courses of at least two antidepressant treatments.Open the glossary, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.

Key facts

Kind of item
Access and funding
Compound
Psilocybin
Condition
Depression
Organisation
Compass Pathways
Jurisdiction
United States
Source
The Microdose (UC Berkeley BCSP) (themicrodose.substack.com)
Published
How this summary was made

The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method

Source: The Microdose (UC Berkeley BCSP) · themicrodose.substack.com

Connected to

Kind of item
Access and funding
Compound
Psilocybin
Condition
Depression
Organisation
Compass Pathways
Jurisdiction
United States

Other recent items on these topics